Relaxin H2 (human) trifluoroacetate salt

Serelaxin (RLX-030), a recombinant form of human gene-2 relaxin targeting the RLN receptor, is a vasoactive peptide hormone with an antifibrotic activity[1][2][3].

Research Areas >> Cardiovascular Disease

Signaling Pathways >> Others >> Others

Research Areas >> Inflammation/Immunology

Serelaxin (0.5 mg/kg per day, subcutaneous administration) produces 20 to 40 ng/mL of circulating hormone, which successfully prevents and reduces fibrosis progression in various experimental models of injury. The doses do not exhibit significant toxicity[1]. Serelaxin restores endothelial function by increasing nitric oxide (NO)-mediated relaxation but not endothelium-derived hyperpolarisation (EDH)[2]. Animal Model: Six- to 8-week-old male mice (on a 129sv or 129sv×C57B6J background, which were equally sensitive to tissue injury and fibrosis)[1]. Dosage: 0.5 mg/kg. Administration: Subcutaneous administration per day for 7 days. Result: Produced 20 to 40 ng/mL of circulating hormone.

[1]. Chrishan S Samuel, et al. Serelaxin Is a More Efficacious Antifibrotic Than Enalapril in an Experimental Model of Heart Disease. Hypertension. 2014 Aug;64(2):315-22.

[2]. Hooi Hooi Ng, et al. Serelaxin Treatment Reverses Vascular Dysfunction and Left Ventricular Hypertrophy in a Mouse Model of Type 1 Diabetes. Sci Rep. 2017 Jan 9;7:39604.

[3]. Serelaxin.